GO
Loading...

Momenta Pharmaceuticals Inc

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. Israel- based Teva is battling to protect a key patent for the $4- billion- a-year MS drug that is...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. The $4- billion- a-year drug accounts for 50 percent of Teva profits, and the patent fight is one...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's...

  • Oct 3- The U.S. Supreme Court's new term is due to begin on Monday. *Texas Department of Housing and Community Affairs v. In July 2013, the appeals court ruled in favor of two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd..

  • TEL AVIV, July 3- Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration, aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis.

  • The case, in U.S. District Court in Washington, D.C., was dismissed on Wednesday as being premature because the FDA had not yet approved or rejected the applications for generic forms of the drug, Teva said.

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • Stocks to Watch: BUD, STZ, WMT & More Monday, 25 Jun 2012 | 12:47 PM ET

    Take a look at some of Monday's midday movers:

  • What's Shaking: Monday's Early Movers Monday, 30 Jan 2012 | 8:28 AM ET

    Take a look at some of Monday morning's early movers:

  • Mad Mail: MedAssets, Momenta Pharmaceuticals and More Saturday, 26 Mar 2011 | 12:45 PM ET

    When someone calls about a stock Cramer doesn't know, he does his homework and follows up.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Small-cap companies with an almost 400% return Thursday, 28 Aug 2008 | 9:53 AM ET

    So far this year, the Russell 2000 index of small-cap companies continues to outperform the Dow, and the S&P 500.  While most of these companies average only a $1 billion dollar market capitalization, some of their returns are proving resilient to an economic slowdown. 

  • Winners & Losers: Retailers Rule Tuesday, 6 Nov 2007 | 5:58 PM ET

    Rising oil prices have not stopped consumers from going to the mall.  Retailer Guess is enjoying a 15% surge in their stock price. The clothing company reported better than expected revenue.